Drug intelligence / Profile preview

SB-007

Development stage
Phase 2
Lead developer
SpliceBio
Modality
Gene Therapies
Administration
Subretinal
01

Overview

**SB-007** is an investigational dual adeno-associated virus gene therapy developed by SpliceBio for autosomal-recessive Stargardt disease type 1 caused by biallelic pathogenic variants in the **ABCA4** gene. It delivers the large ABCA4 coding sequence in two AAV vectors and uses protein splicing to reconstitute expression of native full-length ABCA4 protein in the retina. SB-007 is administered as a single subretinal injection and is being evaluated in the Phase 1/2 ASTRA study. ([splice.bio](https://splice.bio/splicebio-announces-first-patient-dosed-in-phase-1-2-astra-study-of-sb-007-a-dual-aav-gene-therapy-for-stargardt-disease/))

Other names
AAV8 encoding ABCA4 C-regionAAV-8 encoding ABCA4 C-regionAAV 8 encoding ABCA4 C-regionAAV8 encoding ABCA4 N-regionAAV-8 encoding ABCA4 N-regionAAV 8 encoding ABCA4 N-regionABCA4 gene therapyABCA-4 gene therapyABCA 4 gene therapySplicebio ABCA4 therapy
02

Targets

ABCA4

Beyond the preview

Go deeper on SB-007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SB-007.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call